Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.
冠狀動脈旁路移植術後 empagliflozin 預防心房纖維顫動效果的評估：雙盲、隨機、安慰劑對照試驗。
Naunyn Schmiedebergs Arch Pharmacol 2024-07-02
Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
糖尿病患者早期蛋白尿減少與接受鈉葡萄糖共轉運輸蛋白2抑制劑者，初始估計腎小球過濾率下降較快但長期腎臟結果較佳相關。
Diabetes Obes Metab 2024-07-02
Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.
住院病人中2型糖尿病抗糖尿病藥物使用趨勢：一項回顧性單中心世代研究。
BMJ Open 2024-07-01
Exploring the Anti-Cancer Potential of SGLT2 Inhibitors in Breast Cancer Treatment in Pre-clinical and Clinical Studies.
探討SGLT2抑制劑在乳腺癌治療中的抗癌潛力：從臨床前到臨床研究。
Eur J Pharmacol 2024-07-01
In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo.
在冠心病急性心肌梗塞風險高的成年患者中，empagliflozin 在 18 個月內並未降低首次心衰住院或全因死亡的綜合結果。
Ann Intern Med 2024-07-01